Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

Schr�dinger, Inc.

Schrodinger, Inc. (($SDGR)) has held its Q2 earnings call. Read on for the main highlights of the call. Schrodinger’s latest earnings call struck a...

Schrodinger, Inc. Earnings Call Highlights Growth Amid Shift

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Cencora (COR), Takeda Pharmaceutical Company (TAK) and Schrodinge...

Analysts Conflicted on These Healthcare Names: Cencora (COR), Takeda Pharmaceutical Company (TAK) and Schrodinger (SDGR)

In a report released yesterday, Evan Seigerman from BMO Capital maintained a Buy rating on Schrodinger, with a price target of $24.00. The company’...

BMO Capital Reaffirms Their Buy Rating on Schrodinger (SDGR)

BMO Capital analyst Evan Seigerman maintained a Buy rating on Schrodinger today and set a price target of $24.00. According to TipRanks, Seigerman ...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SDGR	$18.16	+1.97%	1.37M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SDGR	$18.16	+2.0%	1.37M
3
4
5
6

SDGR

SDGR

Get Schr�dinger, Inc. Data in Excel

Get Schr�dinger, Inc. Data in Excel